Cantor Fitzgerald Predicts Zura Bio FY2025 Earnings

Zura Bio Limited (NASDAQ:ZURA - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Zura Bio in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer forecasts that the company will post earnings of ($0.40) per share for the year. Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for Zura Bio's current full-year earnings is ($0.65) per share.

Zura Bio (NASDAQ:ZURA - Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.12).

Other analysts also recently issued research reports about the company. Chardan Capital lowered their target price on Zura Bio from $14.00 to $12.00 and set a "buy" rating on the stock in a research note on Friday, November 8th. HC Wainwright reaffirmed a "neutral" rating and set a $5.00 price objective on shares of Zura Bio in a research note on Tuesday, December 24th. Leerink Partnrs raised shares of Zura Bio to a "strong-buy" rating in a report on Monday, November 4th. Finally, Leerink Partners began coverage on shares of Zura Bio in a research report on Monday, November 4th. They set an "outperform" rating and a $15.00 price target on the stock. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $15.80.

Zura Bio Stock Down 3.9 %

NASDAQ:ZURA traded down $0.07 during trading hours on Thursday, hitting $1.72. 579,522 shares of the company were exchanged, compared to its average volume of 354,229. The company's 50 day moving average price is $2.52 and its 200-day moving average price is $3.47. Zura Bio has a 52-week low of $1.67 and a 52-week high of $6.35.

Insider Buying and Selling

In other Zura Bio news, Director Parvinder Thiara sold 1,001,633 shares of Zura Bio stock in a transaction on Monday, November 25th. The shares were sold at an average price of $2.73, for a total transaction of $2,734,458.09. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 22.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Zura Bio

Several hedge funds and other institutional investors have recently modified their holdings of the business. Armistice Capital LLC raised its holdings in Zura Bio by 53.2% in the 2nd quarter. Armistice Capital LLC now owns 2,524,000 shares of the company's stock valued at $8,834,000 after acquiring an additional 876,000 shares during the last quarter. Braidwell LP acquired a new stake in shares of Zura Bio in the third quarter valued at approximately $10,040,000. Point72 Asset Management L.P. purchased a new position in Zura Bio during the second quarter worth approximately $8,446,000. Geode Capital Management LLC grew its holdings in Zura Bio by 70.6% in the 3rd quarter. Geode Capital Management LLC now owns 912,625 shares of the company's stock valued at $3,706,000 after buying an additional 377,545 shares in the last quarter. Finally, Sphera Funds Management LTD. acquired a new stake in shares of Zura Bio in the 3rd quarter worth $2,999,000. 61.14% of the stock is owned by hedge funds and other institutional investors.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.